Specific mechanism for inhibiting platelet adhesion to collagen
AssigneeMerck Patent GmbH
InventorsChristopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
Life of this patent
Estimating the term…
Abstract
The present invention relates to the polypeptide Saratin and its use for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, where the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices or vascular grafts.
Claims16
A medical device having a surface covered with a hydrogel incorporating an amount of biologically active Saratin therein for local delivery therefrom and which is effective to provide an anti-thrombogenic surface.
A vascular graft wherein a hydrogel incorporating an amount of biologically active Saratin is incorporated into an endovascular graft coating which is placed locally on or in a tissue.
Dependencies are inferred from the claim text.